About Acumen Pharmaceuticals
Acumen Pharmaceuticals is a company based in Livermore (United States) founded in 1996.. Acumen Pharmaceuticals has raised $2.2 million across 4 funding rounds from investors including HHS, NeuroVentures and RA Capital. The company has 61 employees as of December 31, 2024. Acumen Pharmaceuticals offers products and services including Sabirnetug (ACU193). Acumen Pharmaceuticals operates in a competitive market with competitors including argenx, MacroGenics, Alexion, Zai Lab and Kodiak Sciences, among others.
- Headquarter Livermore, United States
- Employees 61 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Acumen Pharmaceuticals, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-102.33 M-95.39as on Dec 31, 2024
-
EBITDA
$-113.84 M-86.76as on Dec 31, 2024
-
Total Equity Funding
$2.2 M (USD)
in 4 rounds
-
Latest Funding Round
$35.75 M (USD), Post-IPO
Mar 17, 2026
-
Investors
HHS
& 3 more
-
Employee Count
61
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Acumen Pharmaceuticals
Acumen Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol ABOS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Acumen Pharmaceuticals
Acumen Pharmaceuticals offers a comprehensive portfolio of products and services, including Sabirnetug (ACU193). The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets toxic amyloid beta oligomers to treat early Alzheimer's disease.
Unlock access to complete
Unlock access to complete
Funding Insights of Acumen Pharmaceuticals
Acumen Pharmaceuticals has successfully raised a total of $2.2M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $35.75 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $35.8M
-
First Round
First Round
(17 Aug 2006)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2026 | Amount | Post-IPO - Acumen Pharmaceuticals | Valuation |
investors |
|
| Sep, 2016 | Amount | Grant - Acumen Pharmaceuticals | Valuation |
investors |
|
| May, 2013 | Amount | Private Equity Round - Acumen Pharmaceuticals | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Acumen Pharmaceuticals
Acumen Pharmaceuticals has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, NeuroVentures and RA Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Acumen Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Acumen Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Acumen Pharmaceuticals Comparisons
Competitors of Acumen Pharmaceuticals
Acumen Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as argenx, MacroGenics, Alexion, Zai Lab and Kodiak Sciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company focused on cancer therapeutics development.
|
|
| domain | founded_year | HQ Location |
Therapies for rare and devastating diseases are developed by Alexion.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapies for cancers and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for retinal diseases are developed by the company.
|
|
| domain | founded_year | HQ Location |
Antibody therapies are developed through machine learning and synthetic biology.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Acumen Pharmaceuticals
Frequently Asked Questions about Acumen Pharmaceuticals
When was Acumen Pharmaceuticals founded?
Acumen Pharmaceuticals was founded in 1996 and raised its 1st funding round 10 years after it was founded.
Where is Acumen Pharmaceuticals located?
Acumen Pharmaceuticals is headquartered in Livermore, United States. It is registered at Livermore, California, United States.
Is Acumen Pharmaceuticals a funded company?
Acumen Pharmaceuticals is a funded company, having raised a total of $2.2M across 4 funding rounds to date. The company's 1st funding round was a Private Equity Round of $700K, raised on Aug 17, 2006.
How many employees does Acumen Pharmaceuticals have?
As of Dec 31, 2024, the latest employee count at Acumen Pharmaceuticals is 61.
What does Acumen Pharmaceuticals do?
Acumen Pharmaceuticals was founded in 1996 and is headquartered in Livermore, United States. Monoclonal antibody therapeutics for Alzheimers disease are developed through a proprietary platform focused on fully humanized antibodies selective for abeta oligomers. These antibodies are also intended for use as diagnostic agents to measure abeta oligomer levels in cerebrospinal fluid, supporting efforts in the biotechnology sector.
Who are the top competitors of Acumen Pharmaceuticals?
Acumen Pharmaceuticals's top competitors include argenx, Zai Lab and Kodiak Sciences.
What products or services does Acumen Pharmaceuticals offer?
Acumen Pharmaceuticals offers Sabirnetug (ACU193).
Is Acumen Pharmaceuticals publicly traded?
Yes, Acumen Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol ABOS.
Who are Acumen Pharmaceuticals's investors?
Acumen Pharmaceuticals has 4 investors. Key investors include HHS, NeuroVentures, RA Capital, and Sands Capital.
What is Acumen Pharmaceuticals's ticker symbol?
The ticker symbol of Acumen Pharmaceuticals is ABOS on NASDAQ.